当前位置： SCI文献检索 > JOURNAL OF GASTROENTEROLOGY期刊下所有文献 > Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.

Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.

Abstract：

BACKGROUND:Pancreatic cancer is obstinate and resistant to gemcitabine, a standard chemotherapeutic agent for the disease. We previously showed a therapeutic effect of glycogen synthase kinase-3β (GSK3β) inhibition against gastrointestinal cancer and glioblastoma. Here, we investigated the effect of GSK3β inhibition on pancreatic cancer cell sensitivity to gemcitabine and the underlying molecular mechanism. METHODS:Expression, phosphorylation, and activity of GSK3β in pancreatic cancer cells (PANC-1) were examined by Western immunoblotting and in vitro kinase assay. The combined effect of gemcitabine and a GSK3β inhibitor (AR-A014418) against PANC-1 cells was examined by isobologram and PANC-1 xenografts in mice. Changes in gene expression in PANC-1 cells following GSK3β inhibition were studied by cDNA microarray and reverse transcription (RT)-PCR. RESULTS:PANC-1 cells showed increased GSK3β expression, phosphorylation at tyrosine 216 (active form), and activity compared with non-neoplastic HEK293 cells. Administration of AR-A014418 at pharmacological doses attenuated proliferation of PANC-1 cells and xenografts, and significantly sensitized them to gemcitabine. Isobologram analysis determined that the combined effect was synergistic. DNA microarray analysis detected GSK3β inhibition-associated changes in gene expression in gemcitabine-treated PANC-1 cells. Among these changes, RT-PCR and Western blotting showed that expression of tumor protein 53-induced nuclear protein 1, a gene regulating cell death and DNA repair, was increased by gemcitabine treatment and substantially decreased by GSK3β inhibition. CONCLUSIONS:The results indicate that GSK3β inhibition sensitizes pancreatic cancer cells to gemcitabine with altered expression of genes involved in DNA repair. This study provides insight into the molecular mechanism of gemcitabine resistance and thus a new strategy for pancreatic cancer chemotherapy.

journal_name

J Gastroenterol

journal_title

Journal of gastroenterology

authors

Shimasaki T,Ishigaki Y,Nakamura Y,Takata T,Nakaya N,Nakajima H,Sato I,Zhao X,Kitano A,Kawakami K,Tanaka T,Takegami T,Tomosugi N,Minamoto T,Motoo Y

doi

10.1007/s00535-011-0484-9

subject

Has Abstract

pub_date

2012-03-01 00:00:00

pages

321-33

issue

eissn

0944-1174

issn

1435-5922

journal_volume

pub_type

杂志文章

在线工具

Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.